Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (LBY135)

Catalog No.

DHA29109

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Target

TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O14763

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

LBY135

Clone ID

LBY135

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis., PMID:26843614

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction., PMID:25484045

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors., PMID:23589214

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3., PMID:20884624

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2., PMID:17922877

Document Download

Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (LBY135).pdf